SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) announced that today it granted restricted stock units representing an aggregate of 25,200 shares of Exelixis common stock to nine new employees. The restricted stock unit awards vest as to 1/4th of the (…)
[Read article]
[Source: Business Wire]
BOTHELL, Wash.-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq: SGEN - News) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. The milestone was triggered (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/37adf0/eli_lilly_co_p) has announced the addition of the "Eli Lilly & Co.: PharmaVitae Profile" company profile to their offering. Introduction This analysis examines the historical and (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/d8a430/india_pharmaceutic) has announced the addition of the "India Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed increasing growth rates in the (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/5f5e15/asiapacific_pharm) has announced the addition of the "Asia-Pacific Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed quite healthy growth rates (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/3ceeca/japan_pharmaceutic) has announced the addition of the "Japan Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed fluctuating growth rates in the (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e03d6e/world_pharmaceutic) has announced the addition of the "World Pharmaceutical Market Analysis - A Digest Guide, 2010-2014" report to their offering. World Pharmaceutical Market (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/3bc1b6/taiwan_pharmaceuti) has announced the addition of the "Taiwan Pharmaceutical Market Analysis, 2010-2014" report to their offering. Taiwan Pharmaceutical Market Report - 2010-2014 (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/614240/fixed_dose_combina) has announced the addition of the "Fixed Dose Combination Products" report to their offering. Fixed dose combination (FDC) products are becoming increasingly (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/d4c0da/south_korea_pharma) has announced the addition of the "South Korea Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed fluctuating growth rates in (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/95a2af/china_pharmaceutic) has announced the addition of the "China Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed very high growth rates in the (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e9e8b4/educating_the_mark) has announced the addition of the "Educating the Market: Creating Value Through Support of Continuing Medical Education 2010" report to their offering. Educating (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/29d9d5/australia_pharmace) has announced the addition of the "Australia Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed quite healthy growth rates in (…)
[Read article]
[Source: Business Wire]
Over one-fourth of the 36 million annual outpatient prescriptions filled in the United States are known to have human genomic biomarker information available that predicts drug safety and efficacy, or both. However, to date, we have not systematically implemented strategies to (…)
[Read article]
[Source: NCBI PubMed]
ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo Co., Ltd. (TSE 4568) announced that they will move forward with a Phase 3 clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with non-small cell lung cancer (NSCLC). In (…)
[Read article]
[Source: Medical News Today]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e3c0d9/market_access_in_j) has announced the addition of Decision Resources, Inc.'s new report "Market Access in Japan: New Challenges and Opportunities for the Pharmaceutical Industry" to (…)
[Read article]
[Source: Business Wire]
18 August 2010 Biota Holdings Limited today reported NPAT of $16.2 million for the year ended June 2010, down from $38.2 million in the previous year, which included receipt of a $20.0 million litigation settlement. Relenza royalty income rose to $63.7 million from $45.0 (…)
[Read article]
[Source: BioSpace]
BACKGROUND: Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer. However, infusional fluorouracil-based regimens, requiring continuous infusion and (…)
[Read article]
[Source: NCBI PubMed]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/7f25f4/the_cardiovascular) has announced the addition of the "The Cardiovascular Market Outlook to 2015: Competitive Landscape, Global Market Analysis, Key Trends and Pipeline analysis" (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/243635/mitsubishi_tanabe) has announced the addition of the "Mitsubishi Tanabe Pharma Corporation: PharmaVitae Profile" company profile to their offering. This analysis examines the (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f48fd7/boehringer_ingelhe) has announced the addition of the "Boehringer Ingelheim GmbH: PharmaVitae Profile" company profile to their offering. This analysis examines the historical and (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/89d247/bristolmyers_squi) has announced the addition of the "Bristol-Myers Squibb Co.: PharmaVitae Profile" company profile to their offering. This analysis examines the historical and (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2061ac/effective_social_m) has announced the addition of the "Effective Social Media Marketing Strategies for Pharmaceutical Market" report to their offering. Effective Social Media (…)
[Read article]
[Source: Business Wire]
An obesity-induced diabetes model using genetically normal mouse strains would be invaluable but remains to be established. One reason is that several normal mouse strains are resistant to high-fat diet-induced obesity. In the present study, we show the effectiveness of gold (…)
[Read article]
[Source: NCBI PubMed]
A new study by the Center for Thrombosis Research at Sinai Hospital in Baltimore, MD will examine the utility of point-of-care genetic and platelet function testing to identify patients at risk for a cardiac event after coronary stenting. Therapy will be altered based on the (…)
[Read article]
[Source: Medical News Today]
DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Hypercholesterolemia research database. , based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be fine (…)
[Read article]
[Source: Business Wire]
Quinolone antibacterial agents are extensively utilized in antimicrobial chemotherapy. However, they have been reported to induce arthropathy in juvenile animals, and the mechanism has not been clarified. Recently, we have demonstrated that Dusp1, Tnfrsf12a, Ptgs2, Fos, Mt1a, (…)
[Read article]
[Source: NCBI PubMed]
SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (NASDAQ:EXEL) announced today that Charles Butler, the company s vice president of investor relations and corporate communications, will present at the Canaccord Genuity 30th Annual Growth Conference at 10:30 a.m. EDT (…)
[Read article]
[Source: Business Wire]
The establishment of a new index for the profile of serum protein binding was analyzed theoretically. The in vitro pharmacological activity ratio of the inhibition constant in the absence of serum protein to that in its presence (activity ratio), which represents the extent of (…)
[Read article]
[Source: NCBI PubMed]
SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the second quarter ended June 30, 2010. I m excited to move into the role of CEO and lead the company with a clear sense of focus and urgency as we advance our key (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/990d00/calming_and_sleepi) has announced the addition of the "Calming and Sleeping in Japan" report to their offering. Calming and sleeping products declined 3% to just over 29 billion in (…)
[Read article]
[Source: Business Wire]
PARSIPPANY, N.J., Aug. 4 /PRNewswire/ - Daiichi Sankyo, Inc. and its parent company, Daiichi Sankyo Co., Ltd, (collectively, "Daiichi Sankyo") have reached an agreement with Apotex Inc. and Apotex Corp. (collectively, "Apotex") to settle their patent litigation involving (…)
[Read article]
[Source: BioSpace]
BOTHELL, Wash.-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Eric L. Dobmeier, Chief Business Officer, will speak at the Canaccord Genuity 30th Annual Growth Conference on Tuesday, August 10, 2010, at 9:30 a.m. Eastern Time. A webcast of the (…)
[Read article]
[Source: Business Wire]
WOBURN, Mass.-(BUSINESS WIRE)-ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the second quarter of 2010. and pre-clinical activities are continuing as planned with a B-RAF inhibitor and an FGFR inhibitor. For the quarter ended June 30, 2010, the Company (…)
[Read article]
[Source: Business Wire]
WOBURN, Mass. and TOKYO-(BUSINESS WIRE)-ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced that they will move forward with a Phase 3 clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with (…)
[Read article]
[Source: Business Wire]
WOBURN, Mass. and TOKYO-(BUSINESS WIRE)-ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced that they will move forward with a Phase 3 clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with (…)
[Read article]
[Source: Business Wire]
Imidazo[1,2-b]pyridazine derivatives from high-throughput screening were developed as IKKbeta inhibitors. By the optimization of the 3- and 6-position of imidazo[1,2-b]pyridazine scaffold, cell-free IKKbeta inhibitory activity and TNFalpha inhibitory activity in THP-1 cell (…)
[Read article]
[Source: NCBI PubMed]
WOBURN, Mass. and TOKYO-(BUSINESS WIRE)-ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced that they will move forward with a Phase 3 clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with (…)
[Read article]
[Source: BioSpace]
BOTHELL, Wash., Aug 03, 2010 (BUSINESS WIRE) - Seattle Genetics, Inc. /quotes/comstock/15*!sgen/quotes/nls/sgen (SGEN 12.90, +0.44, +3.53%) announced today that it has expanded its antibody-drug conjugate (ADC) collaboration agreement with Genentech, Inc., a member of the (…)
[Read article]
[Source: BioSpace]
Preparations and in vitro antifungal activities of triazolopyridines, imidazopyridines, and a pyrazolopyridine were reported. Among those scaffolds, triazolopyridine was found to be the specific inhibitor of the synthesis of beta-1,6-glucan, an essential component of the fungal (…)
[Read article]
[Source: NCBI PubMed]
SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) will release its second quarter 2010 financial results on Thursday, August 5, 2010 after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. ET/ 2:00 p.m. PT, in which (…)
[Read article]
[Source: Business Wire]
Objectives Our aim was to investigate the effect of PEGylation on the uptake of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) into rat liver, kidney and spleen, and human liver. Methods Copolymer of polyethyleneglycol allylmethylether and maleamic acid sodium (…)
[Read article]
[Source: NCBI PubMed]